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Background
Ferumoxytol is used for parenteral iron therapy in
patients with chronic kidney disease (CKD). Because of
its uniquely powerful properties as an intravascular MR
contrast agent, there is growing interest in the safety of
ferumoxytol as a possible alternative to gadolinium-
based contrast agents in patients with CKD and in
patients with congenital heart disease. We reviewed the
frequency, type and severity of adverse reactions to feru-
moxytol as an MRI contrast agent over a broad spec-
trum of ages and indications in a single center study.
Methods
Following informed consent and with approval from our
IRB, we performed ferumoxytol enhanced MRA
(FEMRA) for the assessment of pathologic arterial and
/or venous anatomy in 165 patients (age 36 ± 28 years,
range 3 days to 94 years, 38% female). Both bolus and
slow infusions were given (total dose of 4 mg /kg, 166
injections). Sixty-five patients were examined under gen-
eral anesthesia; three had pacemakers and six were preg-
nant. First pass and steady state FEMRA were
performed in 119 patients and 46 patients had only
steady state imaging. Continuous monitoring of ECG,
pulse oximetry, and non-invasive blood pressure was
performed in all patients and the electronic medical
records were reviewed to assess for follow up events.
Results
In all cases, patients remained stable throughout the
FEMRA studies and there were no serious adverse
events. In two patients, systolic blood pressure (SBP)
transiently decreased by 10-15 mmHg and in 22 patients
SBP increased by 10-15 mmHg. In eight patients with
congenital heart disease, blood oxygenation decreased
by 1-5% during the MRI study. Three patients developed
nausea following injection of ferumoxytol but in all
cases the studies were completed successfully.
Conclusions
In our single center experience, there were no serious
adverse events with the use of ferumoxytol for MRI,
whether injected as a bolus or infused slowly. Although
encouraging, more patient studies from multiple centers
will be needed fully to define the safety profile of feru-
moxytol for diagnostic use.
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Figure 1 Patients with continuous monitoring under
anesthesia. Heart rate (HR), systolic (S) and diastolic (D) blood
pressure (BP), pulse oximetry, and end-tidal CO2 immediately
before ferumoxytol injection, immediately post, 30 minutes post,
and >1 hour post injection. Units are BP=mmHg; End-tidal
CO2=mmHg, HR=beats per min, spO2=%
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